Vernalis has a number of potentially high-value drug development programmes in partnership at present. These include two candidates in imuno-oncology, three candidates in oncology and an additional one in asthma and allergic rhinitis.
Current partnered programmes are as follows:
|CPI-444||Imuno-oncology||Corvus||Phase I Results (undisclosed)|
|V2006 (Vipadenant)||Imuno-oncology||Redox/Juno||Partner Newsflow (undisclosed)|
|Bcl-2||Cancer||Servier / Novartis||Phase I Results (undisclosed)|
|Mcl-1||Cancer||Servier / Novartis||Phase I Results (undisclosed)|
|CHR-2797 (Tosedostat)||Cancer||CTI BioPharma||Partner Newsflow|
|RPL554||Asthma / Allergic rhinitis||Verona Pharma||Phase IIb Study Results|